Cargando…

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer

BACKGROUND: Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status. CASE PRESENTATION: We tried palliative chemotherapy with daily low dose oral cyclophosphamid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samaritani, Riccardo, Corrado, Giacomo, Vizza, Enrico, Sbiroli, Carlo
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1863429/ https://www.ncbi.nlm.nih.gov/pubmed/17433113 http://dx.doi.org/10.1186/1471-2407-7-65

Ejemplares similares

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
por: Ferrandina, Gabriella, et al.
Publicado: (2014)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: A case report
por: Peristeri, Dimitra V., et al.
Publicado: (2021)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Metronomic palliative chemotherapy in maxillary sinus tumor
por: Patil, Vijay M., et al.
Publicado: (2016)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Metastatic Primary Duodenal Adeno-Carcinoma Responding to Metronomic Oral Cyclophosphamide Chemotherapy
por: Bandyopadhyay, Anis, et al.
Publicado: (2014)

Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience
por: Pandey, Avinash, et al.
Publicado: (2016)

Metronomic Chemotherapy for Palliative Treatment of Malignant Oral Tumors in Dogs
por: Milevoj, Nina, et al.
Publicado: (2022)

Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis
por: Sharma, Aparna, et al.
Publicado: (2019)

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
por: Alagkiozidis, Ioannis, et al.
Publicado: (2015)

Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center
por: Lu, Qianyi, et al.
Publicado: (2020)

Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion
por: Muñoz, Raquel, et al.
Publicado: (2019)

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
por: Kelley, R K, et al.
Publicado: (2013)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Effectiveness and toxicity of metronomic oral cyclophosphamide for recurrent or platinum-refractory ovarian cancer: A meta-analysis
por: Huang, Lili, et al.
Publicado: (2022)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman Andrés, et al.
Publicado: (2017)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
por: Soriano, Jorge L., et al.
Publicado: (2011)

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
por: Isono-Taniguchi, Roze, et al.
Publicado: (2022)

Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
por: Parshad, Shruti, et al.
Publicado: (2022)

Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?
por: Günther, M, et al.
Publicado: (2008)

Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.
por: Green, J. A., et al.
Publicado: (1988)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
por: Patten, Steven G, et al.
Publicado: (2010)

Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models
por: Mainetti, Leandro E., et al.
Publicado: (2020)

Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit
por: Masci, G, et al.
Publicado: (2012)

Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives
por: Panthi, Vijay Kumar, et al.
Publicado: (2023)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O.G., et al.
Publicado: (2009)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Urinary bladder hemangiosarcoma in a cat treated with partial cystectomy and adjuvant metronomic cyclophosphamide and thalidomide
por: McNally, Abigail, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cv6s7ucrmm14jhb94v1j23t7vb